Khojasteh, N.H., Zakerinia, M., Ramzi, M., & Haghshenas, M. (2000). A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients. Transplantation Proceedings, 32, 596.

DOI Link

Intervention Characteristics/Basic Study Process

Mesna was given to patients undergoing allogeneic bone marrow transplantation and administered high-dose chemotherapy. Doses were administered at 400 mg/m2 at hours 0, 1, 3, 5, 8, 11, 14, 17, and 20. Fluid also was administered at 3,000 mL/m2.

Sample Characteristics

  • N = 11 patients
  • KEY DISEASE CHARACTERISTICS: Four patients had leukemia; others had nonmalignant disorders.

Study Design

  • Prospective, experimental, nonrandomized, convenience sample

Measurement Instruments/Methods

  • Clinical signs and symptoms
  • Daily urinalysis
  • Observed drop in hemoglobin level
  • Patients evaluated for 60 days

Results

Three patients developed transient but asymptomatic hemorrhagic cystitis. One patient developed late onset but moderate hemorrhagic cystitis.

Limitations

  • Very small sample size
  • Only four patients with cancer
  • Mesna hours different than published guidelines
  • Patients with leukemia not separated in the analysis